1Stability and storage
The guidelines and/or procedures were inadequate in ensuring storage and/or transportation conditions would maintain the quality and safe distribution of the drug.
Inspection Record
Clarins Canada Inc. — Health Canada Inspection Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
2Quality unit oversight
The annual product quality review procedure was inadequate.
3Complaint and recall handling
The written procedures for recalls were inadequate.
4Complaint and recall handling
The quality control department's ability to recognize and forward complaints about the quality of a drug to the appropriate person in charge was inadequate. The assessment, recording, follow-up, and/or investigation of complaints and/or other information about potentially defective products was inadequate.
5Other quality system
The availability or the content of the authentic certificate of analysis was inadequate.
6Other quality system
The controls were inadequate for creating, modifying, reviewing, storing, and/or retrieving records.
7Other quality system
The written procedures and records for retaining samples were inadequate.
About this record
Extracted automatically from the document of the Health Canada inspection on 2025-08-26. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
